Publications

2010
  • Sun J, Masterman-Smith MD, Graham NA, Jiao J, Mottahedeh J, Laks DR, Ohashi M, Dejesus J, Kamei KI, Lee KB, Wang H, Yu ZT, Lu YT, Hou S, Li K, Liu M, Zhang N, Wang S, Angenieux B, Panosyan E, Samuels ER, Park J, Williams D, Konkankit V, Nathanson D, van Dam RM, Phelps ME, Wu H, Liau LM, Mischel PS, Lazareff JA, Kornblum HI, Yong WH, Graeber TG, Tseng HR. A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens. Cancer Res. 2010 Jul 14. [PDF]
  • Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel PS, Moore TB, Kornblum HI. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatr Blood Cancer. 2010 Jun 29. [PDF]
  • Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 2010 May 14. [PDF]
  • Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, Macconaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. J Transl Med. 2010 Apr 20;8(1):39. [PDF]
  • Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle d, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.  Proc Natl Acad Sci U S A. 2010 Mar 22. [PDF]
  • Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle. 2010 Jan 6;9(2). [PDF]
2009
  • Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, Deangelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy. Sci Signal. 2009, Dec 15. [PDF]
  • Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic Landscape of Meningiomas. Brain Pathol. 2009 Nov 20. [PDF]
  • Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. Somatic mutations of the Parkinson’s disease–associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2009, Nov 29. [PDF]
  • Mischel P. A case for a science-informed perspective on health care reform. J Clin Invest. 2009 Oct;119(10):2855. [PDF]
  • Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H. PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci U S A. 2009 Oct 21. [PDF]
  • Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel PS, Ng T, Yarden Y. An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis. Curr Biol. 2009 Oct 14. [PDF]
  • Deliang Guo, Isabel J. Hildebrandt, Robert M. Prins, Horacio Soto, Mary M. Mazzotta, Julie Dang, Johannes Czernin,John Y.-J. Shyyh, Andrew D. Watson, Michael Phelps, Caius G. Radu, Timothy F. Cloughesy, and Paul S. Mischel. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA. 2009 Jul 21. [PDF]
  • Akio Iwanami, Timothy F. Cloughesy, and Paul S. Mischel. Striking the balance between PTEN and PDK1: it all depends on the cell context. Gene Dev. 2009. [PDF]
  • Kan V.Lu, Shaojun Zhu, Anna Cvrljevic, Tiffany Huang, Shawn Sarkaria, David Akhavan, Julie Dang, Eduard B. Dinca, Seema B. Plaisier, Isaac Oderberg, Yohan Lee, Zugen Chen, Jeremy S. Caldwell, Yongmin Xie, Joseph A. Loo, David Seligson,Arnab Chakravari, Francis Y. Lee, Roberto Weinmann, Timothy F. Cloughesy, Stanley F. Nelson, Gabriele Bergers, Thomas Graeber, Frank B. Furnari, C. David James, Webster K. Cavenee, Terrance G. Johns, and Paul S. Mischel. Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. Cancer Res 2009. [PDF]
  • McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, NghiemphuP, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K. Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis. Cancer Cell. 2009 Jul 7;16(1):44-54. [PDF]
  • Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR,Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009 Jul;252(1):182-9.[PDF]
  • Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics.2009 Jul;6(3):500-12. [PDF]
  • Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Nghiemphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neuroncol. 2009 Aug 5. [PDF]
  • Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, TaylorB, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc NatlAcad Sci U S A. 2009 May 28. [PDF].
  • Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol. 2009 May 26. [PDF]
  • Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrentglioblastoma: a single-institution experience. Neurology. 2009 Apr 7;72(14):1217-22. [PDF]
  • Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. Neurosphere Formation Is an IndependentPredictor of Clinical Outcome in Malignant Glioma. Stem Cells. 2009 Jan 22;27(4):980-987. [PDF]
  • Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive Imaging of {alpha}V{beta}3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib. Cancer Res. 2009 Mar 24. [PDF]
  • Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009 Mar;92(1):99-105. Epub 2008 Nov 19.” [PDF]
2008
  • Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. (2008) Oct;249(1):268-77.” [PDF]
  • Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. (2008) Oct 21;1:52.” [PDF]
  • Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC; North Central Cancer Treatment Group Study N0177. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008 Dec 1;26(34):5603-9. Epub 2008 Oct 27.” [PDF]
  • Landon J. Inge, Sigrid A. Rajasekaran, Koji Yoshimoto, Paul S. Mischel, William McBride, Elliot Landaw and Ayyappan K. Rajasekaran. Evidence for a potential tumor suppressor role for the Na,K-ATPase ß1- subunit. 23: 459-467. ” Histol Histopathol (2008). [PDF]
  • De la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JT, Frank DA, Mischel PS, Louis DN, Bonni A. (2008). Deregulation of a STAT3-IL8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness. The Journal of Neuroscience- In Press. [PDF]
  • Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Yongkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS*, Mellinghoff IK* Sawyers CL* (* Co-Senior authors). (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5(1):e8.[PDF]
  • Jindra PT, Hsueh A, Hong L, Gjertson D, Shen XD, Gao F, Dang J, Mischel PS, Baldwin WM 3rd, Fishbein MC, Kupiec-Weglinski JW, Reed EF.(2008) Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol. 180(4):2214-24.[PDF]
  • Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel PS, Liau LM, Bergsneider M, Pope W, Selch M. Cloughesy TF, (2008). Phase II Pilot Study of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. Int J Radiat Oncol Biol Phys. March 2008.[PDF]
  • Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R. Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel PS, Terskikh AV, Kornblum HI (2008). Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res. 86(1):48-6.[PDF]
  • Yoshimoto K, Dang J, Zhu S, Nathanson D, Huange T, Dumont R. Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee Wk, Cloughesy TF, Mischel PS.(2008). Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 14(2):488-93.[PDF]
2007
  • Beroukihm R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau LM, Mischel PS, CLoughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff Ik, Sellers WR (2007). Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 104(50):2007.[PDF]
  • Weaver JD, Vinters HV, Koretz B, Xiong Z, Msichel PS, Kado D.(2007). Lymphomatosis cerebri presenting as rapidly progressive dementia. Neurologist. 13(3):150-3. [PDF]
  • Carlson M, Pope W, Horvath S, Braunstein J, Nghiemphu P, Tso C, Mellinghoff IK, Lai A, Liau L, Mischel PS, Dong J, Nelson SF, Cloughesy TF. (2007) Relationship between survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. Clinical Cancer Research, 13 (9): 2592-2598. [PDF]
  • Mellinghoff IK, Cloughesy TF, Mischel PS. (2007) PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research. 13(2):378-381. [PDF]
  • Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, Wang M, Feng W, Zander T, MacConnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong K, Gabriel K, Beroukhim R, Peyton M, Barretina J, Dutt, A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK,Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MS, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, and Garraway LA (2007). High-throughput oncogene mutation profiling in human cancer. Nature Genetics,39(3): 347-51. [PDF]
  • Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murry JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO. (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 13(1):84-8. [PDF]
2006
  • Lee JC, Huang JH, Feng W, DeBiasi R, King JC, Beroiukhim R, Yuza Y, Greulich H, Thomas RK, Paez G, Peck T, Linhart D, Glatt KA, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Nghiemphu P, Mischel PS, Cloughesy TF, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, and Melliinghoff IK. (2006) EGFR activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec 19;3(12):2264-2272 [ PDF]
  • Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O’Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel PS, Pieper RO, Cloughesy TF, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domian. PLoS Med, Dec 3(12):e485. [PDF]
  • Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Shuping, Q, Chen, Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, Febbo PG, Kornblum HI, Cloughesy TF, Nelson SF, and Mischel PS. (2006) Analysis of Oncogenic Signaling Networks in Glioblastoma Identifies ASPM as a Molecular Target. PNAS, 103(46):17402-07.[PDF]
  • Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. (2006) mTOR inhibition promotes response to EGFR kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. In press. [PDF]
  • Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA, McBride WH. (2006) HDJ-2 as a Target for Radiosensitization of Glioblastoma Multiforme Cells by the Farnesyltransferase Inhibitor R115777 and the Role of the p53/p21 Pathway. Cancer Research. 66(13):6756-6762. [PDF]
  • Carlson MR, Zhang B, Fang Z, Mischel PS, Horvath S, Nelson SF. (2006) Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks. BMC Genomics 3;7:40. [PDF]
  • Mischel PS and Cloughesy TF (2006) Using molecular information to guide brain tumor therapy. Nature Clinical Practice Neurology, 2:232-233. [PDF]
  • Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology66(8):1258-60. [PDF]
  • Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. (2006) Distinct Transcription Profiles of Primary and Secondary Glioblastoma Subgroups. Cancer Research, 66(1):159-67. [PDF]
  • Tso CL, Shintaku P, Chen J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. (2006) Primary gioblastoma express mesenchymal stem-like properties. Molecular Cancer Research, 4(9):607-1). [PDF] 
2005
  • Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JHY, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, StokoeD , Prados M, Cloughesy TF, Sawyers CL and Mischel PS. (2005) Molecular determinants of EGFR kinase inhibitor response in glioblastoma. New England Journal of Medicine, 353(19)2012-2024. [PDF]
  • Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF and Mischel PS. (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. Journal of Biological Chemistry 280(29):26953-64. [PDF]
  • Pope WB, Sayre J, Perlina A, Villablanca P, Mischel PS, Cloughesy TF (2005). MR imaging correlates of survival in patients with high grade gliomas. American Journal of Neuroradiology 26(10)2466-74. [PDF]
  • Stillman BN, Mischel PS, Baum LG. (2005) New Roles for Galectins in Brain Tumors – From Prognostic Markers to Therapeutic Targets. Brain Pathology, 15:124-132. [PDF]
  • Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF and Roth MD. (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research, 11(15):5515-25. [PDF]
  • Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergscheider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. (2005) Imaging Proliferation in Brain Tumors with 18F-FLT-PET: comparison with 18F-FDG. Journal of Nuclear Medicine, 46(6):945-52. [PDF]
  • Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. (2005). Mol Brain Res. 2005 20;136(1-2):99-103. [PDF]
2004
  • ;Lu KV, Jong, K, Rajasekaran AK, Cloughesy TF, and Mischel PS. (2004) Upregulation of Tissue Inhibitor of Metalloproteinases (TIMP)-2 Promotes Matrix Metalloproteinase (MMP)-2 Activation and Cell Invasion in a Human Glioblastoma Cell Line. Laboratory Investigation 84(1):8-20. [PDF]
  • Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. (2004) p53 Disruption Profoundly Alters the Response of Human Glioblastoma Cells to DNA Topoisomerase I Inhibiton. Oncogene 23(6):1283-1290. [PDF]
  • Frieje WA, Castro-Vargas FE, Fang, Z, Horvath S, Cloughesy TF, Liau LM, Mischel PS, Nelson SF. (2004)Gene Expression Profiling of Gliomas Strongly Predicts Survival. Cancer Research 64(18):6503-6510. [PDF]
  • Mischel PS, Cloughesy TF and Nelson SF. (2004) DNA-Microarray Analysis of Brain Cancer: Molecular Classification for Therapy. Nature Reviews Neuroscience 5(10): 782-792. [PDF]
2003 and Previous
  • Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith B, Sawyers CL and Mischel PS. (2003) Analysis of the PI3K Signaling Pathway in Glioblastoma Patients In Vivo. Cancer Research 63(11):2742-2746. [PDF]
  • Mischel PS and Cloughesy TF. Targeted molecular therapy of Glioblastoma. (2003) Brain Pathology 13(1):52-61. [PDF]
  • Mischel PS, Nelson SF, and Cloughesy TF. Molecular analysis of glioblastoma: Pathway profiling and its implications for patient therapy. (2003) Cancer Biology and Therapy 2(3):242-247. [PDF]
  • Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau L, Cloughesy T, Nelson SF. (2003) Identification of Molecular Subtypes of Glioblastoma by Gene Expression Profiling. Oncogene 22(15):2361-2372. [PDF]
  • Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS*, Nelson SF* (*Co-Senior authors). (2003) Gene Expression Profiling Identifies Distinct Subtypes of Gliomas. Oncogene 22(31):4918-4923. [PDF]
  • Choe G, Jouben-Steele L, Park JK, Vinters HV, Liau L., Cloughesy TF, Mischel PS. (2002) Active MMP-9 expression is associated with primary glioblastoma subtype. Clinical Cancer Research 8(9): 2894-2901. [PDF]
  • Mischel PS, Smith SG, Vining ER, Valletta JS, Mobley WC, Reichardt LF. (2001) The extracellular domain of p75NTR is necessary to inhibit Neurotrophin-3 signaling through TrkA. Journal of Biological Chemistry 276:11294-11301. [PDF]
  • Mischel PS, Umbach JA, Eskandri S, Smith SG, Gundersen CB and Zampighi GA. (2002) Nerve growth factor signals via pre-existing TrkA receptor oligomers. Biophysical Journal 83:968-976. [PDF]
  • Catania MG, Mischel PS, Vinters HV. (2001) Hamartin and tuberin interaction with the G2/M cyclin-dependent kinase cdk1 and its regulatory cyclins A and B. Journal of Neuropathology and Experimental Neurology 60(7):711-723. [PDF]
  • Liau LM, Black KL, Martin NA, Sykes SN, Brontstein JM, Joubin-Steele L, Mischel PS, Belldegrun A, Cloughesy TF. (2000) Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogenic major histocompatibility complex class I-matched tumor peptides. Neurosurgical Focus 9:1-5.[PDF]
Home      About      Projects     People     Publications     News     Funding     Links      Positions     Contact
Copyright © 2010 Paul Mischel, M.D.